Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has provided an announcement.
Chimeric Therapeutics Ltd. has reported significant progress in its clinical trials, with promising early results from its CHM CORE-NK trial at MD Anderson Cancer Center, showing complete remission in two out of three AML patients. The company is also advancing its CHM CDH17 CAR-T program, having safely progressed to a higher dose level without dose-limiting toxicities, and is well-funded to continue its trials. Financially, Chimeric has strengthened its position through non-dilutive funding and successful capital raises, positioning it to prioritize clinical development and data generation.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. operates in the biotechnology industry, focusing on the development of cell therapies for cancer treatment. The company is involved in clinical trials for its innovative therapies, including CHM CORE-NK and CHM CDH17 CAR-T, targeting conditions like acute myeloid leukemia (AML) and glioblastoma. Chimeric leverages partnerships with institutions like MD Anderson Cancer Center and Case Western Reserve University to advance its research and development efforts.
Technical Sentiment Signal: Sell
Current Market Cap: A$7.4M
For a thorough assessment of CHM stock, go to TipRanks’ Stock Analysis page.